Women's Angiographic Vitamin and Estrogen trial:
Judith Hsia(University of Colorado Denver), David D. Waters(San Francisco General Hospital), Naji Younes(George Washington University), Michael A. Proschan(National Institute of Allergy and Infectious Diseases), Barbara V. Howard(MedStar Health), William J. Rogers(Universidad Nacional del Centro de la Provincia de Buenos Aires), Vera Bittner(University of Alabama at Birmingham), David J. Gordon(University of Iowa), Jean‐Claude Tardif(Montreal Heart Institute), Pamela Ouyang(Johns Hopkins University), Ivan Barofsky(Johns Hopkins University), Paul D. Thompson, Michael W. Steffes(University of Minnesota), Frederick R. Cobb(Duke University), Lyall Higginson(University of Ottawa), Joel Verter(George Washington University), Edwin L. Alderman(Stanford University)
Cited by 24
Related Papers
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
|Circulation|1989|3.2k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k